BRUIN CLL-322: A randomised, phase 3 study of pirtobrutinib plus venetoclax and rituximab compared to venetoclax plus rituximab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL)
A phase 3 this trial testing a treatment combination in people who have had previous treatment for chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04965493
Trial aim and background
The aim of this trial is to compare the efficacy and safety of pirtobruitinib (LOXO-305) plus venetoclax and rituximab with venetoclax and rituximab in people with (CLL)/(SLL) who have received at least one previous treatment. Pirtobrutinib (LOXO-305) is a BTK inhibitor.
People who take part in this trial are randomly allocated to one of two treatment groups:
- Arm A: pirtobrutinib (LOXO-305) plus venetoclax and rituximab.
- Arm B: venetoclax and rituximab.
You are told which treatment you are having and given information about it. Participation could last up to five years.
Who can enter
Adults with CLL/SLL requiring treatment, and who have had one previous treatment regimen may be eligible for this trial.
Locations
Recruitment is taking place in the following UK locations:
- Derriford Hospital, Plymouth, Devon
- Leicester Royal Infrimary, Leicester
- St James's University Hospital, Leeds, West Yorkshire
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/study/NCT04965493
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.